Cambridge Biolabs provides exclusive access to ultra-sensitive DNA adduct testing. DNA adducts are cancer-causing compounds covalently bonded to DNA. Adducts are used as biomarkers of exposure because presence of an adduct demonstrates exposure to the compound.
The pharmaceutical industry currently uses the Ames test to study the mutagenic effect of a compound but this test suffers from known shortcomings. The use of DNA adduct testing can increase the compound’s safety profile. New and old compounds considered for drug development by the pharmaceutical industry and drugs considered for approval by the FDA should the subject of DNA adduct testing. These compounds should be subjected to DNA adduct testing to elucidate the potential for DNA-binding that may result in mutation and carcinogenesis.
DNA adduct testing is important for compounds that are not intended for human use as well. Organizations like the EPA, for example, have great use for adduct testing on compounds that they are studying and suspect are carcinogenic.